MALVERN, PA — Venatorx Pharmaceuticals recently granted exclusive commercial rights to Italy’s Menarini Group for its novel antibiotic, cefepime-taniborbactam. The agreement extends to 96 countries in Europe, Latin America, Middle East, Turkey, North Africa, and the Commonwealth of Independent States (CIS), pending approval from relevant health authorities.
The deal involves an upfront licensing fee, additional payments tied to research and development, regulatory milestones, sales targets, and potential royalties based on net sales. This arrangement showcases Venatorx’s confidence in Menarini’s global reach and experience in commercializing infectious disease products, including antibiotics.
“Cefepime-taniborbactam has the potential to address critical global unmet medical needs by treating the rapidly growing number of drug-resistant gram-negative infections,” said Christopher J. Burns, Chief Executive Officer of Venatorx. “Menarini’s expansive commercial infrastructure and significant experience make them the ideal partner to bring our novel antibiotic to key markets.”
For Menarini, acquiring the rights to cefepime-taniborbactam represents a significant addition to their existing AMR anti-infectives portfolio. It also aligns with their commitment to building a robust antibiotics portfolio focusing on pathogens responsible for the majority of antibiotic resistance.
Elcin Barker Ergun, CEO of the Menarini Group, expressed optimism about the partnership and its potential benefits. “By leveraging our expertise and expansive commercial infrastructure, we can optimize the commercialization of cefepime-taniborbactam, ensuring patient access to this vital medicine across our global footprint,” said Ergun.
This alliance marks a significant step in the ongoing battle against antibiotic resistance, a pressing global health concern. The successful commercialization of cefepime-taniborbactam could pave the way for a new generation of antibiotics, providing hope for patients and healthcare providers alike.
As drug-resistant infections continue to pose a significant threat to global health, partnerships like this between Venatorx and Menarini are crucial. By combining innovative research with commercial expertise, these companies can bring life-saving treatments to patients in need. The pharmaceutical industry will undoubtedly be watching this partnership closely to see how it shapes the future of antibiotic development and distribution.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.